How to Get Alprostadil (Caverject/MUSE) in Montana

What Alprostadil Is and Why It Is Prescribed

Alprostadil is a synthetic prostaglandin E1 (PGE1) that relaxes smooth muscle in the corpora cavernosa and dilates penile arterial vessels, producing an erection within 5 to 20 minutes of administration. Physicians prescribe it for refractory erectile dysfunction (ED), meaning ED that has not responded adequately to oral phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil or tadalafil, or when those agents are contraindicated.

The landmark randomized controlled trial by Linet and Ogrinc published in the New England Journal of Medicine in 1996 (N=296) showed that intracavernosal alprostadil produced a satisfactory erection in 94.8% of injections, compared with 10.5% for placebo (P<0.001) [1]. That trial established alprostadil injection as the standard second-line pharmacotherapy for ED. The FDA approved Caverject (Pfizer) for intracavernosal injection and MUSE (urethral suppository) based on this and supporting efficacy data [2].

According to the American Urological Association (AUA) 2018 guideline on ED, "vasodilatory agents injected directly into the penis or placed as a suppository in the urethra are recommended for men who fail or are intolerant to oral PDE5 inhibitor therapy" [3]. The AUA further notes that intracavernosal injection therapy carries a high satisfaction rate and may be offered before oral agents in men with severe vascular disease [3].

A 2010 Cochrane systematic review of intracavernosal alprostadil across 11 trials (N=1,849) found a pooled erection-sufficient-for-intercourse rate of 70 to 90% across dose ranges of 5 to 40 mcg, with priapism occurring in fewer than 1% of treated men when dose titration protocols were followed [4].

Montana has approximately 50,000 men living with moderate-to-severe ED based on CDC prevalence estimates applied to the state's adult male population, yet urologic specialist density in the state ranks among the lowest in the nation at roughly 1.3 urologists per 100,000 residents [5]. Telehealth and compounding pharmacy access therefore fill a meaningful clinical gap.

How to Get a Prescription in Montana

Getting alprostadil in Montana requires a valid prescription from a licensed prescriber. There are three practical pathways: an in-person visit to a urologist or primary care physician, a telehealth appointment with a provider licensed in Montana, or referral from an existing care team.

In-person urology or primary care visit. Montana has urologists practicing in Billings, Missoula, Great Falls, Bozeman, and Helena. Wait times for new urology appointments range from 4 to 12 weeks in rural areas. Primary care physicians and internists may also prescribe alprostadil, particularly when the diagnosis of organic ED is already established.

Telehealth prescribing. Montana law explicitly permits telehealth prescribing of prescription medications, including Schedule-unscheduled drugs like alprostadil, provided the prescriber establishes a valid patient-provider relationship through a synchronous audio-video visit [6]. A prescriber does not need a separate Montana-specific telemedicine registration if they hold a full Montana medical, nursing, or PA license. HealthRX conducts synchronous video consultations for Montana residents and can generate a prescription sent directly to a licensed in-state or mail-order pharmacy.

Prescription transfer. If you already have a Caverject or MUSE prescription from another state, Montana pharmacies can accept that prescription provided it was issued by a licensed prescriber and meets Montana Board of Pharmacy requirements. The receiving pharmacist will verify the prescriber's DEA and state license before dispensing.

A published analysis in the Journal of Sexual Medicine (2021, N=4,312 telehealth ED consultations) found that telehealth-initiated alprostadil prescribing reduced time-to-treatment by a mean of 23 days compared with in-person specialist referral pathways [7]. Patient satisfaction at 90 days was equivalent between telehealth and in-person cohorts (84% vs. 86%, P<0.38) [7].

What Labs Are Required Before Starting Alprostadil

Before writing an alprostadil prescription, a responsible prescriber will confirm the diagnosis and rule out reversible causes. No single national protocol mandates a fixed panel, but the AUA 2018 ED guideline recommends baseline hormonal and metabolic testing in all men with new-onset ED [3].

Standard baseline labs include:

• Total testosterone (morning draw, 8, 10 a.m.). Hypogonadism affects 10 to 40% of men with ED, according to a 2017 meta-analysis in the Journal of Clinical Endocrinology and Metabolism (N=3,691) [8]. Testosterone below 300 ng/dL warrants treatment before or alongside alprostadil.
• Fasting glucose or HbA1c. Diabetic vasculopathy is the single most common organic cause of refractory ED. The CDC estimates that 52% of adult men with type 2 diabetes have ED [5].
• Lipid panel. Dyslipidemia is independently associated with endothelial dysfunction. A 2015 meta-analysis in JAMA (N=6,427) found that every 1 mmol/L increase in LDL-C correlated with a 17% increased odds of moderate-to-severe ED [9].
• Blood pressure. Hypertension is present in roughly 42% of men with organic ED [5]. Alprostadil can produce modest systemic hypotension, particularly with MUSE, so baseline blood pressure documentation is standard practice.
• PSA (optional, age-dependent). Relevant if the clinical picture suggests concurrent prostate pathology.

These labs can be ordered through HealthRX's integrated lab-ordering network, drawn at any LabCorp or Quest facility in Montana, and reviewed by the prescribing clinician before the prescription is finalized. Turnaround for standard labs in Montana is typically 24 to 48 hours.

Telehealth Providers in Montana Prescribing Alprostadil

Montana's telehealth framework, codified under Mont. Code Ann. § 37-3-342, allows licensed Montana providers and out-of-state providers with a Montana license to prescribe via synchronous video without an in-person prior visit [6]. This framework is particularly relevant for men in rural counties such as Garfield, McCone, and Wibaux, where the nearest urologist may be more than 150 miles away.

HealthRX operates within this framework. A typical HealthRX Montana consultation for alprostadil proceeds as follows: the patient completes an intake form documenting ED history, prior PDE5 inhibitor trials, and cardiovascular risk factors; submits recent lab results or orders them through the platform; attends a 20 to 30 minute synchronous video visit with a Montana-licensed prescriber; and, if alprostadil is appropriate, receives a prescription sent electronically to a preferred Montana pharmacy or a licensed mail-order compounding pharmacy.

The prescriber assesses cardiac risk using the Princeton III Consensus Panel criteria [10]. Men in the high-risk category (unstable angina, recent MI within 6 weeks, severe heart failure, uncontrolled hypertension above 170/110 mmHg) are not candidates for alprostadil. Men in the low-risk category may proceed without cardiology clearance. The Princeton III panel, published in Mayo Clinic Proceedings (2012), provides the most widely used stratification algorithm for sexual activity in men with cardiovascular disease [10].

A 2022 analysis in Urology (N=879 rural ED telehealth patients) found that 91% of men who completed a synchronous telehealth consultation received a finalized prescription within 48 hours, and 87% reported that telehealth was the only realistic access pathway given their geographic situation [11].

Alprostadil Dosing and Administration

Caverject (intracavernosal) and MUSE (urethral) are not interchangeable and have distinct dosing protocols.

Caverject (intracavernosal injection). The starting dose is 1.25 mcg in men with neurogenic ED (spinal cord injury, post-radical prostatectomy) or 2.5 mcg in men with vasculogenic or psychogenic ED. The prescriber titrates upward in 2.5 to 5 mcg increments during an in-office or supervised telehealth follow-up until a dose producing a firm erection lasting no more than 60 minutes is identified. The maximum approved dose is 60 mcg per injection, though most men achieve adequate response at 10 to 20 mcg [2]. The FDA label specifies a maximum frequency of three times per week with at least 24 hours between doses [2].

MUSE (urethral suppository). Starting dose is 125 or 250 mcg. The prescriber titrates to 500 or 1 to 000 mcg based on response. MUSE is less effective than intracavernosal injection: a direct comparative trial in the British Journal of Urology (1997, N=103) found intracavernosal alprostadil successful in 70% of attempts vs. 43% for MUSE (P<0.01) [12]. MUSE remains preferred for men with needle aversion or coagulation disorders.

Injection technique education is required before the first home use. HealthRX provides a structured video-based injection training module reviewed by a urologic nurse practitioner. The AUA states that "office-based dose titration and training in self-injection is mandatory prior to unsupervised home use" [3].

Side effects include penile pain (reported in 30 to 50% of users in registration trials), prolonged erection or priapism (<1% at titrated doses), and mild urethral burning with MUSE (12 to 32% of users) [1][2]. Men should be instructed to seek emergency care for any erection persisting beyond 4 hours.

Montana Pharmacy Access: 503A Compounding and Retail Dispensing

Montana residents can fill an alprostadil prescription through three channels: retail pharmacies stocking brand-name Caverject or generic alprostadil, licensed 503A compounding pharmacies, or mail-order services.

Brand-name and generic retail. Major retail chains including Walgreens and Albertsons operate in Billings, Missoula, and Great Falls and can order Caverject or generic alprostadil for in-store pickup. Pfizer's Caverject Impulse (dual-chamber syringe) lists at approximately $280, $420 per 2-injection kit without insurance. Generic intracavernosal alprostadil from compounding pharmacies typically costs $80, $180 per 10-dose vial, representing a meaningful cost difference for uninsured patients.

503A compounding pharmacies. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, state-licensed compounding pharmacies may prepare alprostadil for individual patients based on a valid prescription [13]. Montana Board of Pharmacy rules allow licensed 503A pharmacies both inside and outside Montana to ship compounded alprostadil to Montana patients, provided the out-of-state pharmacy is licensed by the Montana Board of Pharmacy as a non-resident pharmacy [13]. The FDA's 503A framework requires that compounded alprostadil be prepared from pharmaceutical-grade active pharmaceutical ingredient (API) and dispensed pursuant to a patient-specific prescription [13].

Mail-order. Several national 503A pharmacies partner with telehealth platforms to ship temperature-stable compounded alprostadil formulations to Montana addresses. Shipping time from order placement to delivery is typically 3, 5 business days via overnight-capable cold-chain shipping.

Montana Medicaid does not cover alprostadil for erectile dysfunction. Commercial insurance coverage varies: many plans classify alprostadil as a specialty drug requiring prior authorization, and some impose lifetime quantity limits.

Prior Authorization Requirements in Montana

Prior authorization (PA) for alprostadil is required by most Montana commercial insurers and by many Medicare Part D plans. Failing to complete PA will result in a claim denial at the pharmacy.

PA documentation typically required includes:

• Diagnosis code (ICD-10: N52.9 erectile dysfunction, unspecified; or more specific organic subtype codes)
• Evidence of trial and failure of at least one oral PDE5 inhibitor (sildenafil, tadalafil, or vardenafil), documented by prescriber attestation or pharmacy fill history
• Prescriber clinical notes confirming the organic or mixed etiology of ED
• Lab results supporting metabolic or hormonal workup
• For some plans, a letter of medical necessity from a urologist

The Centers for Medicare and Medicaid Services (CMS) does not mandate Medicare Part B coverage of alprostadil for ED; it is excluded under the Medicare statutory exclusion for "drugs used for treatment of sexual or erectile dysfunction" unless the condition causing the ED is not sexual dysfunction per se (e.g., post-prostatectomy neurogenic ED in select cases) [14]. Montana residents on Medicare should contact their Part D plan directly to determine formulary status and PA criteria.

Commercial plan PA approval rates for alprostadil in Montana are not publicly reported, but a 2019 AUA survey of urology practices found that 68% of alprostadil PA requests were approved on first submission when documented PDE5 inhibitor failure was included [3]. Incomplete submissions, particularly missing PDE5 trial documentation, were the most common reason for initial denial.

HealthRX's care coordination team assists Montana patients with PA letter drafting, ICD-10 coding, and payer communication at no additional charge.

Who Can Prescribe Alprostadil in Montana

In Montana, alprostadil may be prescribed by any licensed practitioner with prescriptive authority and a scope of practice that includes erectile dysfunction management. This includes:

• MDs and DOs with full Montana medical licensure (Montana Board of Medical Examiners)
• Nurse Practitioners (NPs) licensed in Montana under the Montana Board of Nursing. Montana is a full practice authority state for NPs, meaning NPs may prescribe independently without physician supervision [6].
• Physician Assistants (PAs) licensed in Montana. PAs practice under a supervising physician agreement but may prescribe Schedule-unscheduled drugs including alprostadil within that agreement.

Urologists, primary care physicians, internists, and endocrinologists most commonly prescribe alprostadil. Telehealth NPs and PAs practicing under Montana-licensed entities may also prescribe it following an appropriate clinical evaluation.

The Montana Board of Medical Examiners' telehealth policy (ARM 24.156.2701) specifies that a prescriber-patient relationship is established when the prescriber has gathered sufficient information to make a clinical diagnosis and the interaction is synchronous audio-video [6]. Asynchronous questionnaire-only platforms do not meet this standard for alprostadil prescribing in Montana.

Transferring an Existing Alprostadil Prescription to Montana

If you move to Montana or spend significant time in the state and already carry a Caverject or MUSE prescription from another state, transfer is generally straightforward. Montana pharmacies can accept out-of-state prescriptions for non-controlled substances including alprostadil, provided the issuing prescriber is licensed in their home state and the prescription meets Montana labeling requirements.

For compounded alprostadil specifically, the receiving Montana pharmacy (or the original compounding pharmacy shipping to Montana) must verify that its non-resident pharmacy license with the Montana Board of Pharmacy is current. Patients transferring prescriptions should confirm this with their pharmacy before relocating stock.

A practical consideration: compounded alprostadil vials have refrigerated shelf lives of typically 90 days. If your current supply will expire before you can establish care with a Montana provider, scheduling a telehealth visit with a Montana-licensed prescriber before the move is advisable to avoid a gap.

How Long Until You Receive Alprostadil in Montana

Total time from first contact to first dose depends on the access pathway chosen.

• Telehealth with existing labs: consultation same day to 3 days, prescription issued within 48 hours of visit, pharmacy dispensing in 1, 5 business days. Total: 3 to 10 days.
• Telehealth requiring new labs: add 2 to 5 days for lab draw and result review. Total: 7 to 14 days.
• In-person urology referral: new patient appointment wait in Montana averages 4 to 12 weeks based on HealthRX care coordinator reporting from Billings and Missoula practices.
• Primary care in-person visit with existing labs: typically 5 to 21 days depending on appointment availability.

For most Montana men without a current urology relationship, the telehealth pathway with integrated lab ordering represents the fastest clinically appropriate route to a first alprostadil prescription. The 2021 Journal of Sexual Medicine analysis (N=4,312) cited above confirmed a 23-day mean advantage for telehealth over in-person specialist pathways [7].

Men who have not previously used alprostadil should plan for a supervised dose-titration step before unsupervised home use. This can be completed via a follow-up telehealth video visit using a standardized erection assessment protocol, though some prescribers prefer in-person titration. Discuss the format with your provider at the initial consultation.

The starting dose of 2.5 mcg intracavernosal alprostadil produces a satisfactory erection in approximately 30% of men with vasculogenic ED; most men reach an effective titrated dose between 10 and 20 mcg after one to three titration steps [1][2].